ACM
HRTX icon

AIGH Capital Management’s Heron Therapeutics HRTX Stock Holding History

AIGH Capital Management’s Portfolio HRTX Stock Details HRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-3,009,257
Closed -$6.23M – 44
2025
Q2 		$6.23M Buy
3,009,257
+231,057
+8% +$472K 2.8% 17
2025
Q1 		$6.11M Buy
+2,778,200
New +$5.39M 2.53% 16

Other funds holding HRTX

RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CC
Clearline Capital New York $1.93B AUM 38.13% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $160M AUM 517.12% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PCM
Palisade Capital Management Fort Lee, New Jersey $3B AUM 14% 1-Year Est. Return
TC
Tejara Capital London, United Kingdom $303M AUM 5.43% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

AIGH Capital Management's HRTX Position: Q3 2025 in Review

AIGH Capital Management sold out of Heron Therapeutics (HRTX) in Q3 2025, closing a stake of 3,009,257 shares — an estimated $6.23M sold.

AIGH Capital Management first reported a position in HRTX in Q1 2025 and held it in 2 quarters. The position peaked at $6.23M in Q2 2025. 172 funds tracked by Wall St. Rank hold HRTX as of Q3 2025.

  • AIGH Capital Management reported no remaining Heron Therapeutics position as of Q3 2025 after selling out during the quarter.
  • AIGH Capital Management sold 3,009,257 Heron Therapeutics shares in Q3 2025, an estimated $6.23M.
  • AIGH Capital Management first reported a position in Heron Therapeutics in Q1 2025 and held it in 2 quarters.
  • AIGH Capital Management's Heron Therapeutics position peaked at $6.23M in Q2 2025.
  • 172 funds tracked by Wall St. Rank held Heron Therapeutics as of Q3 2025.

Based on AIGH Capital Management's 13F filing for Q3 2025, filed 31 Oct 2025.